Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 605-612
Open Access | Times Cited: 531

Showing 1-25 of 531 citing articles:

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10285, pp. 1637-1645
Open Access | Times Cited: 1016
A living WHO guideline on drugs for covid-19
Arnav Agarwal, Beverley J. Hunt, Miriam Stegemann, et al.
BMJ (2020), pp. m3379-m3379
Open Access | Times Cited: 962
Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Peré Domingo, Isabel Mur, Gràcia Mateo, et al.
JAMA (2021) Vol. 326, Iss. 6, pp. 499-499
Open Access | Times Cited: 600
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10289, pp. 2049-2059
Open Access | Times Cited: 471
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou, Garyphallia Poulakou, Haralampos Milionis, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1752-1760
Open Access | Times Cited: 451
Pathophysiology of COVID-19-associated acute kidney injury
Matthieu Legrand, Samira Bell, Lui G. Forni, et al.
Nature Reviews Nephrology (2021) Vol. 17, Iss. 11, pp. 751-764
Open Access | Times Cited: 417
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 665-676
Open Access | Times Cited: 354
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Peter Horby, Guilherme Pessoa-Amorim, Leon Peto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 302
An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies
Hin Fung Tsang, Lawrence Chan, William C. Cho, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 7, pp. 877-888
Closed Access | Times Cited: 286
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Christopher Butler, Jienchi Dorward, Ly‐Mee Yu, et al.
The Lancet (2021) Vol. 397, Iss. 10279, pp. 1063-1074
Open Access | Times Cited: 272
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 399, Iss. 10320, pp. 143-151
Open Access | Times Cited: 257
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 400, Iss. 10349, pp. 359-368
Open Access | Times Cited: 254
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia
Lene Russell, Kis Rønn Uhre, Ann Louise Syraach Lindgaard, et al.
JAMA (2021) Vol. 326, Iss. 18, pp. 1807-1807
Open Access | Times Cited: 228
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
Ryan S. Thwaites, Ashley Sanchez Sevilla Uruchurtu, Matthew K. Siggins, et al.
Science Immunology (2021) Vol. 6, Iss. 57
Open Access | Times Cited: 214
COVID-19 and metabolic disease: mechanisms and clinical management
Charlotte Steenblock, Peter E. H. Schwarz, Barbara Ludwig, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 11, pp. 786-798
Open Access | Times Cited: 206
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Sujin Kang, Tadamitsu Kishimoto
Experimental & Molecular Medicine (2021) Vol. 53, Iss. 7, pp. 1116-1123
Open Access | Times Cited: 205
Host genetic factors determining COVID-19 susceptibility and severity
Thirumalaisamy P. Velavan, Srinivas Reddy Pallerla, Jule Rüter, et al.
EBioMedicine (2021) Vol. 72, pp. 103629-103629
Open Access | Times Cited: 182
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
Oliver J. McElvaney, Gerard F. Curley, Stefan Rose‐John, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 6, pp. 643-654
Open Access | Times Cited: 181
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1419-1426
Open Access | Times Cited: 171
Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection
Jia-Tsrong Jan, Ting-Jen Rachel Cheng, Yu-Pu Juang, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 5
Open Access | Times Cited: 169
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19
Roberto Caricchio, Antonio Abbate, И. Г. Гордеев, et al.
JAMA (2021) Vol. 326, Iss. 3, pp. 230-230
Open Access | Times Cited: 157
Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells
Daniel Chauss, Tilo Freiwald, Reuben McGregor, et al.
Nature Immunology (2021) Vol. 23, Iss. 1, pp. 62-74
Open Access | Times Cited: 155
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
Evdoxia Kyriazopoulou, Thomas Huet, Giulio Cavalli, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 10, pp. e690-e697
Open Access | Times Cited: 152
Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study
Raquel Carbonell, Silvia Urgelés, Alejandro Rodríguez, et al.
The Lancet Regional Health - Europe (2021) Vol. 11, pp. 100243-100243
Open Access | Times Cited: 149
Page 1 - Next Page

Scroll to top